Breaking Finance News

Axsome Therapeutics Inc (NASDAQ:AXSM) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.

Having a price of $8.17, Axsome Therapeutics Inc (NASDAQ:AXSM) traded -3.88% lower on the day. The last stock close price is down -2.60% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. Axsome Therapeutics Inc has recorded a 50-day average of $7.62 and a two hundred day average of $8.39. Volume of trade was down over the average, with 18,719 shares of AXSM changing hands under the typical 29,845

Zacks Investment Research has downgraded Axsome Therapeutics Inc (NASDAQ:AXSM) to Sell in a statement released on 10/11/2016.

On 10/03/2016, Brean Capital released a statement about Axsome Therapeutics Inc (NASDAQ:AXSM) upped the target price from $0.00 to $20.00 that suggested an upside of 1.54%.

Performance Chart

Axsome Therapeutics Inc (NASDAQ:AXSM)

With a total market value of $0, Axsome Therapeutics Inc has with a one year low of $5.37 and a one year high of $15.74 .

A total of 3 equity analysts have released a research note on AXSM. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $23.00.

Brief Synopsis About Axsome Therapeutics Inc (NASDAQ:AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *